OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
-0.0033
-33.00%
0.0062 / 0.01 (30000 x 431533)
AppYea, Inc begins the process to acquire Sleepx Ltd. and Nexense Technologies USA Inc.
Boca Raton, FL, and Rehovot, Israel (OTC Pink: APYP) AppYea, Inc. (“AppYea” or the “Company”) begun the process to acquire 100% of the outstanding shares of SleepX Ltd., a company formed under the laws of Israel (“SleepX”) and Nexense Technologies USA Inc., a Delaware corporation.
Todd Violette, CEO of AppYea stated, "I have been very impressed with the SleepX management team in Israel and SleepX’s products and technology. SleepX holds a portfolio of patents and products designed to prevent snoring and sleep apnea, which I believe present a unique opportunity for AppYea."
AppYea management's review of information from Research and Markets September 18, 2020 industry report, indicates the global sleep apnea device market is forecast to increase to US$9.29 billion in 2024, growing at a compounded annual growth rate of 7.94% between 2020-2024. The same report found that the fastest-growing regional market was North America, with the highest incidence of obstructive sleep apnea cases, provided that Europe also represents a large available market.
"SleepX has developed a unique technology for monitoring sleep apnea. The Technology and IP are protected via international patents - sleep apnea detection and sleep phases analysis through sound wave analysis, developed in the Biomedical Department of Ben Gurion University in Beer Sheva, Israel. Based on this technology, one of the leading products SleepX offers is a unique night bracelet for the treatment of snoring using artificial Intelligence", said Bary Molchadsky, CEO of SleepX.
Caution
All potential acquisitions are subject to various closing conditions, which may not be met in the estimated timeframe, or at all. The acquisition may prove to be more costly or time-consuming than expected, and regulatory and other approvals required for closing may not be obtained. In order to complete the two acquisitions, there could be dilution to existing shareholders.
Forward-Looking Statement
This Press Release includes forward-looking statements. In particular, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, including, but not limited to the ability of the parties to close the transaction contemplated by the non-binding Letter of Intent (the “LOI”), and enter into definitive agreements, on a timely basis, if at all; the occurrence of any event, change or other circumstances that could give rise to the right of one or all of the parties to the LOI or the definitive agreements (collectively, the “LOI Parties”) to terminate the LOI or definitive agreements (if entered into); the effect of such terminations; the outcome of any legal proceedings that may be instituted against LOI Parties or their respective affiliates; the ability to obtain regulatory and other approvals and meet other closing conditions to the definitive agreement on a timely basis or at all, including the risk that regulatory and other approvals required for the definitive agreement are not obtained on a timely basis or at all, or are obtained subject to conditions that are not anticipated or that could adversely affect the combined company or the expected benefits of the transaction; prevailing economic, market, regulatory or business conditions, or changes in such conditions, negatively affecting the parties; risks associated with COVID-19 and the global response thereto; risks that the transaction disrupts the Company’s or SleepX’s current plans and operations; failing to fully realize anticipated cost savings and other anticipated benefits of the planned acquisition when expected or at all; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; the ability of SleepX and the Company to retain and hire key personnel; the diversion of management’s attention from ongoing business operations; uncertainty as to the long-term value of the common stock of the combined company following the planned acquisition; the significant dilution which will be created to ownership interests of the Company in connection with the closing of the transactions contemplated by the LOI; the continued availability of capital and financing following the transaction; the ability of the Company to obtain sufficient funding to support its operations through the closing date of the transaction; and the business, economic and political conditions in the markets in which LOI Parties operate. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct its own forward-looking statements, except as required by law. Also, the Company takes no obligation to update or correct information prepared by third parties that are not paid for by the Company.
For AppYea Inc.
Contact information:
Investor Relations
Phone: 800-674-3561 Ext 704 text messaging is available also.
Email: info@appyea.com
For SleepX
Please use the contact page on the website.